Shots: Roche divulges results from three P-III studies of Tecentriq (atezolizumab) clinical development program in TNBC at the ESMO Virtual Congress 2020. The P-III IMpassion031 assessing Tecentriq + CT vs […]readmore
Tags : Triple-Negative Breast Cancer
Shots: The P-III IMpassion131 study involves assessing of Tecentriq + paclitaxel vs PBO + paclitaxel, in 651 people in a ratio (2:1) with previously untreated, inoperable, LA/ m-TNBC The study […]readmore
Shots: Tecentriq (atezolizumab, q2w) Intravenous Infusion 840mg has been listed on the NIH reimbursement price list and launched by Chugai as an optimal formulation to treat PD-L1-positive hormone receptor-negative and […]readmore
Shots: The approval is based on P-III IMpassion130 study assessing Tecentriq + nab-paclitaxel vs PBO + nab-paclitaxel in 902 patients in ratio (1:1) with unresectable locally advanced or metastatic TNBC […]readmore
Shots: The P-II KEYNOTE-890 study results involve assessing of Keytruda (200mg, IV) + TAVO (tavokinogene telseplasmid) in 25 patients with heavily pretreated, CT/radiotherapy refractory mTNBC who failed an average of […]readmore
Shots: The P-III KEYNOTE-119 study results involves assessing of Keytruda (pembrolizumab, 200mg) as monothx. vs CT (capecitabine/eribulin/gemcitabine/vinorelbine) for the 2L/3L treatment in 622 patients in ratio (1:1) with metastatic triple-negative […]readmore
MedTech
Pharma
Roche’s Ventana PD-L1 (SP142) Receives FDA’s Approval for Identifying Triple-Negative
Shots: The approval is based on IMpassion130 study assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with advanced or mTNBC with no prior therapy The Ventana PD-L1 (SP142) […]readmore